MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Ovid therapeutics Inc

Fechado

SetorSaúde

1.65 -4.62

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.62

Máximo

1.74

Indicadores-chave

By Trading Economics

Rendimento

5.6M

-4.7M

Vendas

6.1M

6.3M

Margem de lucro

-74.681

Funcionários

23

EBITDA

7.3M

-5.1M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+166.86% upside

Dividendos

By Dow Jones

Próximos Ganhos

10 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

73M

112M

Abertura anterior

6.27

Fecho anterior

1.65

Sentimento de Notícias

By Acuity

50%

50%

166 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de out. de 2025, 23:25 UTC

Grandes Movimentos do Mercado

Salesforce Rises on New FY30 Financial Targets

15 de out. de 2025, 18:52 UTC

Ganhos
Grandes Movimentos do Mercado

Prologis Shares Gain on Raised Outlook, Data Center Growth

15 de out. de 2025, 18:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software to Buy U.K.'s Tecvia Holding

15 de out. de 2025, 17:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15 de out. de 2025, 17:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15 de out. de 2025, 23:48 UTC

Conversa de Mercado

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15 de out. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 de out. de 2025, 22:37 UTC

Conversa de Mercado

Economic Stars Are Aligning for RBA -- Market Talk

15 de out. de 2025, 21:44 UTC

Ganhos

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de out. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15 de out. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15 de out. de 2025, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15 de out. de 2025, 20:34 UTC

Ganhos

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15 de out. de 2025, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15 de out. de 2025, 20:17 UTC

Aquisições, Fusões, Aquisições de Empresas

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15 de out. de 2025, 19:06 UTC

Ganhos

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Post Back-to-Back Losses -- Market Talk

15 de out. de 2025, 18:46 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15 de out. de 2025, 18:23 UTC

Ganhos

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15 de out. de 2025, 17:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15 de out. de 2025, 17:34 UTC

Conversa de Mercado

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15 de out. de 2025, 16:57 UTC

Ganhos

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15 de out. de 2025, 16:51 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica Doesn't Disclose Financial Details

15 de out. de 2025, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15 de out. de 2025, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15 de out. de 2025, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15 de out. de 2025, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15 de out. de 2025, 16:47 UTC

Aquisições, Fusões, Aquisições de Empresas

EssilorLuxottica Buys Ikerian

15 de out. de 2025, 16:34 UTC

Conversa de Mercado

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

166.86% parte superior

Previsão para 12 meses

Média 4.67 USD  166.86%

Máximo 7 USD

Mínimo 1.5 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

8

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

166 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat